Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Rhei Pharma Gaining on SFDA Approval of MuGard™

publication date: Jun 17, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Rhei Pharmaceuticals was told by the SFDA that its application for China marketing of MuGard™ is complete. MuGard is an oral mouthwash that protects against oral mucositis, a side effect of chemotherapy and radiation treatment. Rhei expects final marketing approval of the product in the second half of the year. MuGard was developed by Access Pharmaceuticals in the US. Rhei, a privately held company based in Hong Kong, also has offices in China and the US. Rhei specializes in bringing western drugs to China. More details....

Stock Symbol: (OTCBB: ACCP)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...